Gallus doubles biologics capacity with acquisition of CMO Laureate

By Dan Stanton

- Last updated on GMT

Gallus buys Laureate to double process development services
Gallus buys Laureate to double process development services
Gallus Biopharmaceuticals has doubled its biologics process development services with the acquisition of contract manufacturer Laureate.

Gallus operates a Centre of Excellence for third-party process development (PD) and manufacture of biopharmaceuticals from its site in St. Louis, Missouri. The acquisition of Laureate is set to double PD capacity, adding full protein characterisation, testing and clinical fill-finish capabilities from a second site in Princeton, New Jersey.

“There is sufficient demand from clients for these services,”​ Gallus' CEO Mark Bamforth told Biopharma-Reporter.com and “Gallus expects to maintain and grow both facilities.”

Within the industry, he continued, “there is some consolidation of biologics focused contract manufacturing organisations (CMOs) with a limited number that have established commercial capabilities.It is part of Gallus’ strategy to look for opportunities for M&A that complement the strong organic growth at Gallus’ existing sites.”

Financial details of the acquisition have not been disclosed.

New Jersey to Missouri

Between the St. Louis and newly acquired Princeton facilities, the firm will use a mixture of single-use platforms and stainless steel bioreactors - including Thermo Scientific’s Hyclone and GE Healthcare’s Xcellerex (both single-use) - for manufacturing volumes between 50L and 2,000L.

Gallus will select the site most relevant to suit a client’s requirements, Bamforth told us.

“The St. Louis site has deep perfusion expertise so clients requiring perfusion technology would be best served from there,”​ he said, whilst “the Princeton site has deep experience handling more complex molecules, such as fusion proteins, so those would be best served from there.”

However, “there may be some clients’ whose needs involve activity at both sites, such as bulk production in St. Louis and clinical fill-finish at the Princeton site​,” though “eventually, successful molecules will transfer to St. Louis for commercial bulk manufacturing.”

The 200,000sq ft St. Louis site was acquired by the newly formed CMO Gallus in 2011 from Centocor​, and has approval from every major regulator. Last year the firm completed a $20m (€14.8m) expansion​, doubling the size of the PD laboratories and equipping it to supply monoclonal antibodies for clinical trials.

Related news

Show more

Related products

show more

High quality excipients and formulation support

High quality excipients and formulation support

Roquette Pharma Solutions | 09-Nov-2021 | Product Brochure

As the world grapples with the effects of ongoing health crises, the market is expanding quickly as developers shift their focus to proactive therapeutics....

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars